Fabienne Baffert
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 02, 2023
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Journal: PloS one
Published: April 10, 2019
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Journal: Investigational new drugs
Published: April 30, 2018
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Journal: Cancer cell
Published: November 03, 2014
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Journal: Cancer cell
Published: November 03, 2014
JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 02, 2013
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Journal: Cancer discovery
Published: June 12, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Journal: The Journal of experimental medicine
Published: January 25, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026